Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 9.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 122,473 shares of the company’s stock after selling 13,078 shares during the quarter. Ritholtz Wealth Management’s holdings in Amneal Pharmaceuticals were worth $970,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in Amneal Pharmaceuticals by 17.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after acquiring an additional 641,405 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after purchasing an additional 378,136 shares in the last quarter. State Street Corp lifted its position in shares of Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after purchasing an additional 127,753 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Amneal Pharmaceuticals by 1.9% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company’s stock valued at $16,954,000 after purchasing an additional 50,000 shares in the last quarter. Finally, BlackBarn Capital Partners LP increased its stake in Amneal Pharmaceuticals by 41.5% during the 2nd quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock worth $12,700,000 after buying an additional 586,703 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gautam Patel sold 17,410 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the completion of the transaction, the director now directly owns 2,031,476 shares of the company’s stock, valued at $16,272,122.76. This trade represents a 0.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 123,657 shares of company stock worth $1,016,687. 17.46% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AMRX shares. Truist Financial raised their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, Piper Sandler upped their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Stock Down 0.6 %

Shares of Amneal Pharmaceuticals stock opened at $8.26 on Monday. The business has a 50-day moving average price of $8.18 and a 200 day moving average price of $8.12. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $9.48. The firm has a market cap of $2.56 billion, a P/E ratio of -12.15 and a beta of 1.10.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.